Ceritinib provides longer progression-free survival than chemotherapy in phase III trial of ALK rearranged lung cancer treatment

Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study.